Related Experiment Videos
Maintenance chemotherapy in advanced ovarian cancer: the US experience
1The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. mmarkman@mdanderson.org
Abstract:
The somewhat controversial results of a Southwest Oncology Group/Gynecologic Oncology Group phase 3 randomized trial have revealed that a maintenance strategy consisting of 12 cycles of single-agent paclitaxel (175 mg/m(2) over 3 h every 28 days), delivered to women with advanced ovarian cancer who have achieved a clinically defined complete response to primary platinum-paclitaxel chemotherapy, significantly improves progression-free survival compared to delivery of three cycles of the same treatment regimen. While it is not possible to provide a definitive statement regarding the impact of this management approach on overall survival, in an exploratory analysis, patients who initiated this study with a baseline CA-125 level
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...